Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bioventus Inc. stock logo
BVS
Bioventus
$6.92
-0.1%
$6.67
$5.81
$14.38
$568.44M0.83395,928 shs499,759 shs
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
$3.68
+1.4%
$3.68
$1.60
$16.55
$273.16M1.17952,907 shs371,049 shs
InfuSystem Holdings, Inc. stock logo
INFU
InfuSystem
$8.83
+17.4%
$6.11
$4.61
$9.97
$180.36M1.81157,035 shs654,482 shs
SeaSpine Holdings Co. stock logo
SPNE
SeaSpine
$9.54
$8.53
$5.48
$14.23
$354.92M1.31822,700 shs1.16 million shs
10 Stocks Set to Soar in Fall 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bioventus Inc. stock logo
BVS
Bioventus
0.00%+11.97%-6.36%+3.28%-7.24%
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
0.00%0.00%-10.46%+56.60%-68.30%
InfuSystem Holdings, Inc. stock logo
INFU
InfuSystem
0.00%+54.91%+42.65%+64.43%+27.97%
SeaSpine Holdings Co. stock logo
SPNE
SeaSpine
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Bioventus Inc. stock logo
BVS
Bioventus
2.8835 of 5 stars
3.40.00.00.01.63.31.3
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
2.5138 of 5 stars
4.61.00.00.02.60.80.0
InfuSystem Holdings, Inc. stock logo
INFU
InfuSystem
3.0042 of 5 stars
2.03.00.00.03.14.21.9
SeaSpine Holdings Co. stock logo
SPNE
SeaSpine
0.5639 of 5 stars
0.00.00.03.90.01.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bioventus Inc. stock logo
BVS
Bioventus
2.75
Moderate Buy$13.7598.70% Upside
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
3.18
Buy$12.56241.18% Upside
InfuSystem Holdings, Inc. stock logo
INFU
InfuSystem
4.00
Strong Buy$12.5041.56% Upside
SeaSpine Holdings Co. stock logo
SPNE
SeaSpine
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest SPNE, BVS, CATX, and INFU Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/22/2025
InfuSystem Holdings, Inc. stock logo
INFU
InfuSystem
Roth Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$12.00
7/21/2025
InfuSystem Holdings, Inc. stock logo
INFU
InfuSystem
Roth Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
7/12/2025
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
Lifesci Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
7/7/2025
Bioventus Inc. stock logo
BVS
Bioventus
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$12.00
6/23/2025
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$9.00 ➝ $12.00
6/23/2025
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$11.00
6/3/2025
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeOutperform ➝ Moderate Buy$15.00 ➝ $16.00
5/14/2025
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$10.00 ➝ $8.00
5/13/2025
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$11.00
(Data available from 8/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bioventus Inc. stock logo
BVS
Bioventus
$564.14M1.01$0.55 per share12.58$2.80 per share2.47
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
N/AN/AN/AN/A$2.67 per shareN/A
InfuSystem Holdings, Inc. stock logo
INFU
InfuSystem
$139.89M1.29$0.69 per share12.79$2.47 per share3.57
SeaSpine Holdings Co. stock logo
SPNE
SeaSpine
$191.45M1.85N/AN/A$8.57 per share1.11
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bioventus Inc. stock logo
BVS
Bioventus
-$156.23MN/AN/A15.04N/A-7.11%15.61%4.01%N/A
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
-$46.51MN/A0.00N/AN/A-4,096.66%-27.40%-23.16%8/13/2025 (Estimated)
InfuSystem Holdings, Inc. stock logo
INFU
InfuSystem
$870K$0.23147.1928.48N/A1.12%2.78%1.41%N/A
SeaSpine Holdings Co. stock logo
SPNE
SeaSpine
-$54.35M-$1.77N/AN/AN/A-28.22%-22.16%-17.09%N/A

Latest SPNE, BVS, CATX, and INFU Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2025N/A
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
-$0.30N/AN/AN/A$0.17 millionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Bioventus Inc. stock logo
BVS
Bioventus
N/AN/AN/AN/AN/A
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
N/AN/AN/AN/AN/A
InfuSystem Holdings, Inc. stock logo
INFU
InfuSystem
N/AN/AN/AN/AN/A
SeaSpine Holdings Co. stock logo
SPNE
SeaSpine
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bioventus Inc. stock logo
BVS
Bioventus
1.85
1.41
0.99
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
N/A
9.60
9.60
InfuSystem Holdings, Inc. stock logo
INFU
InfuSystem
0.50
1.98
1.59
SeaSpine Holdings Co. stock logo
SPNE
SeaSpine
0.09
3.18
1.65

Institutional Ownership

CompanyInstitutional Ownership
Bioventus Inc. stock logo
BVS
Bioventus
62.94%
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
54.66%
InfuSystem Holdings, Inc. stock logo
INFU
InfuSystem
71.13%
SeaSpine Holdings Co. stock logo
SPNE
SeaSpine
70.81%

Insider Ownership

CompanyInsider Ownership
Bioventus Inc. stock logo
BVS
Bioventus
33.00%
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
3.72%
InfuSystem Holdings, Inc. stock logo
INFU
InfuSystem
11.40%
SeaSpine Holdings Co. stock logo
SPNE
SeaSpine
9.32%
CompanyEmployeesShares OutstandingFree FloatOptionable
Bioventus Inc. stock logo
BVS
Bioventus
1,20082.14 million54.46 millionNot Optionable
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
7074.23 million65.21 millionOptionable
InfuSystem Holdings, Inc. stock logo
INFU
InfuSystem
41020.43 million19.10 millionOptionable
SeaSpine Holdings Co. stock logo
SPNE
SeaSpine
52337.20 million33.74 millionOptionable

Recent News About These Companies

Corewell Health adds 7D Flash
Orthofix faces class action suit for 'misleading investors'
Orthofix Shareholders Sue Over Misstatements on Fired Executives
Spine Biologics Market Size to Achieve USD 6.95 Bn by 2033
The 2024 Medtech Big 100: The world’s largest medical device companies
The Smartest Guys in Spine Are Buying ATEC Stock
Q2 2024 Orthofix Medical Inc Earnings Call

New MarketBeat Followers Over Time

Media Sentiment Over Time

Bioventus stock logo

Bioventus NYSE:BVS

$6.92 -0.01 (-0.14%)
Closing price 08/8/2025 04:00 PM Eastern
Extended Trading
$6.92 +0.00 (+0.07%)
As of 08/8/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Bioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain. Its surgical solutions comprise bone graft substitutes that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries; and ultrasonic products used for precise bone cutting and sculpting, soft tissue management, and tissue debridement, in various surgeries, including minimally invasive applications. The company's product include, Osteoamp, an allograft-derived bone graft for bone grafting procedures; Exponent matrix for posterolateral spine procedures; Purebone for bone grafting procedures; Signafuse bone graft; Interfuse bone graft; Osteomatrix+ synthetic bone graft; Extractor for autologous cell and bone marrow extraction; reficio bone matrix; nexus ultrasonic surgical system; bonescalpel surgical solution; SonaStar for surgical procedures; and SonicOne ultrasonic cleansing and debridement system. The company's restorative therapies include a bone stimulation system and devices to help patients regain leg or hand function due to stroke, multiple sclerosis, or other central nervous system disorders. Its products include exogen, a bone healing system; L300 GO, a foot drop system; H200 rehabilitation system; Vector, a body weight support system; and Bioness integrated therapy system. It developing Talisman pulse generator and receiver for peripheral nerve stimulation. The company was founded in 2011 and is headquartered in Durham, North Carolina.

Perspective Therapeutics stock logo

Perspective Therapeutics NYSE:CATX

$3.68 +0.05 (+1.38%)
Closing price 08/8/2025 04:00 PM Eastern
Extended Trading
$3.66 -0.03 (-0.68%)
As of 08/8/2025 07:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.

InfuSystem stock logo

InfuSystem NYSE:INFU

$8.83 +1.31 (+17.42%)
Closing price 08/8/2025 04:00 PM Eastern
Extended Trading
$9.16 +0.33 (+3.69%)
As of 08/8/2025 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states. The company also sells, rents, and leases new and pre-owned pole-mounted and ambulatory infusion pumps, and other durable medical equipment; sells treatment-related consumables; and provides biomedical recertification, maintenance, and repair services for oncology practices, as well as other healthcare site settings comprising hospitals, home care and home infusion providers, skilled nursing and acute care facilities, pain centers, and others. In addition, it offers local and field-based customer support, as well as operates pump service and repair centers. The company was incorporated in 2005 and is headquartered in Rochester Hills, Michigan.

SeaSpine stock logo

SeaSpine NASDAQ:SPNE

As of January 4, 2023, SeaSpine Holdings Corporation was acquired by Orthofix Medical Inc. SeaSpine Holdings Corporation, a medical technology company, focuses on the design, development, and commercialization of surgical solutions for the treatment of spinal disorders in the United States and internationally. It offers orthobiologics and spinal implant solutions for the neurosurgeons and orthopedic spine surgeons to perform fusion procedures in the lumbar, thoracic, and cervical spine. The company's orthobiologics products include demineralized bone matrix (DBM), collagen ceramic matrices, demineralized cancellous allograft bone products, and synthetic bone void fillers to improve bone fusion rates in a range of orthopedic surgeries, including spine, hip, and extremities procedures. It also offers orthobiologics products in various forms, such as fibers, putties, pastes, strips, and DBM. In addition, the company offers implant products for spinal decompression, alignment, stabilization, and image-guided surgical solutions, as well as a surgical navigation system used to facilitate fusion in degenerative, minimally invasive, and complex spinal deformity procedures throughout the lumbar, thoracic, and cervical regions of the spine. SeaSpine Holdings Corporation was incorporated in 2015 and is headquartered in Carlsbad, California.